[HB-EGF is a promising target molecule for ovarian cancer].
Miyamoto
Shingo
S
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University.
Yagi
Hiroshi
H
Tanaka
Yoshihiro
Y
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001426:Bacterial Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D002455:Cell Division / Q000235:genetics*; D015195:Drug Design; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors* / Q000502:physiology*; D066246:ErbB Receptors / Q000502:physiology*; D005260:Female; D066257:Heparin-binding EGF-like Growth Factor; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008246:Lysophospholipids / Q000502:physiology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics / Q000502:physiology
D000970:Antineoplastic Agents; D001426:Bacterial Proteins; C587883:HBEGF protein, human; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008246:Lysophospholipids; C028581:CRM197 (non-toxic variant of diphtheria toxin); D004815:Epidermal Growth Factor; D066246:ErbB Receptors; C032881:lysophosphatidic acid